Accueil » Actualités » Publications scientifiques » Posters » 2016

2016

EORTC, 2016 - Beneficial outcome of combination therapy with 4 -1BB mAb targeting antibody

Oncodesign, Dijon (France), Center Georges François Leclerc, Dijon (France),

TELECHARGER
WPC November, 2016 - Immuno-oncology therapeutics technological progression toward a huge preclinical challenge of humanizing the immune component in mice-

Oncodesign, Dijon (France), Center Georges François Leclerc, Dijon (France), IMODI Consortium (France - www.imodi-cancer.com)

TELECHARGER
WPC June, 2016 - From syngeneic to humanized mouse models: addressing the needs for novel immunotherapies

Oncodesign, Dijon ; INSERM 866, Université de Bourgogne, Dijon ; Center Georges François Leclerc, Dijon

TELECHARGER
AACR April, 2016 - Humanized mouse models for evaluation of cancer therapies

Oncodesign, Dijon, (France) Center Georges Francois Leclerc, Dijon (France)

TELECHARGER
AACR April, 2016 - Efficacy of PD-1/PD-L1 pathway disruptors in syngeneic models

INSERM 866, Université de Bourgogne, Dijon, (France) Center Georges Francois Leclerc, Dijon, (France) Oncodesign, Dijon (France)

TELECHARGER
AACR April, 2016 - Innovative and predictive models against cancer: an IMODI integrative approach

Ariana Pharmaceuticals, Paris; 2 Biofortis Merieux Nutrisciences, Saint-Herblain; 3 CTI-BIOTECH, Lyon; 4 Modul-Bio, Marseille; 5 Oncodesign, Dijon ; 6 Oncomedics, Limoges; 7 Ipsen Innovation, Les Ulis; 8 Pierre Fabre Research Institut, St-Julien-en-Genevois; 9 Sanofi, Vitry-sur-Seine; 10 Servier Research Institut, Suresnes; 11 CNRS U5059, Toulouse; 12 Centre Georges François Leclerc, Dijon;13 Toulouse Hospital; 14 Centre Léon Bérard, Lyon; 15 INSERM U938, Paris; 16 INSERM U1033, Lyon; 17 INSERM U1037, Toulouse; 18 INSERM U1052, Lyon; 19 INSERM U1068, Marseille; 20 INSERM U1111, Lyon; 21 Fondation Synergie Lyon Cancer, Lyon; 22 Strasbourg University; 23 Pitié-Salpetrière Hospital, Paris - FRANCE

TELECHARGER
AACR April, 2016 - Enhanced antitumor activity achieved by combining the oncolytic peptide LTX-315 with anti-PD-L1 antibody

Lytix Biopharma AS, Norway; Department of Medical Biology, Faculty of Health Sciences, University of Tromso, Norway; Oncodesign, Dijon, France

TELECHARGER
AACR February, 2016 - A Novel Holistic and Integrative Approach with Patient-Derived Tumor Models

Ariana Pharmaceuticals ; Biofortis Merieux Nutrisciences ; CTI-BIOTECH ; Modul-Bio ; Oncodesign ; OncoMedics ; Ipsen Innovation ; Pierre Fabre Research Institut ; Sanofi ; Servier Research Institut ; CNRS U5059 ; Centre Georges François Leclerc ; Toulouse Hospital ; Centre Léon Bérard ; INSERM ; Synergie Lyon Cancer ; Strasbourg University ; Pitié-Salpetrière Hospital

TELECHARGER